DNMT3A and hepatocellular carcinoma: Taken together, DNMT3A demonstrates multi-layered evidence—ranging from early overexpression in diseased liver to diagnostic accuracy in HCV-related cohorts, and from correlation with recurrence and survival to functional ties with cancer stemness—making it an actionable epigenetic biomarker in HCC [17,18,19].